Zephyrx to Integrate Niox FeNO
Zephyrx will integrate FeNO by Niox into the Zephyrx Respiratory Cloud Platform to advance clinical research, according to a joint press release.
Tag: FeNO
All
Latest
Zephyrx to Integrate Niox FeNO
Zephyrx will integrate FeNO by Niox into the Zephyrx Respiratory Cloud Platform to advance clinical research, according to a joint press release.
Read More
On-demand Webinar: Guiding Asthma Care with Spirometry, FeNO, and Oscillometry
Watch RT Magazine’s on-demand webinar on asthma care and learn more about how spirometry, FeNO, and oscillometry are used in diagnosis and disease management.
Read More
Products 2023: PFT & Spirometry
A closer look as some of the latest spirometers and pulmonary function testing (PFT) diagnostic devices on the market from coVita, FutureMed, MGC Diagnostics, and Vitalograph.
Read More
Caire’s Fenom Pro Upgrade Includes 6-Sec Test Mode
Caire’s Fenom Pro fractional exhaled nitric oxide (FeNO) device can now be upgraded to include a 6-second test mode available for ages 6 and up.
Read More
RT 2023 March-April: The Digital Edition
In RT’s March-April 2023 issue, we report on the Top 5 takeaways from the 2023 GOLD Report on COPD; arterial blood gases in the NICU; and supplemental oxygen therapy for pediatric RSV patients.
Read More
Vitalograph to Market NIOX FeNO Device
Vitalograph is now an authorized distributor of NIOX point-of-care fractional exhaled nitric oxide (FeNO) testing devices in the United States.
Read More
MGC Diagnostics to Distribute FeNObreath Test Monitor
MGC Diagnostics has partnered with Bedfont Scientific Ltd to distribute the FeNObreath test monitor to hospitals and remote locations.
Read More
Circassia Expanding FeNO Asthma Testing into Primary Care
Asthma FeNO testing will be available in more US primary care settings as the result of a new national distribution model for Circassia Inc’s NIOX Vero FeNO testing device.
Read More
FeNO Recommended for Asthma: New Clinical Practice Guideline
A new guideline from the American Thoracic Society recommends the use of fractional exhaled nitric oxide (FeNO) in patients with asthma in whom treatment is being considered.
Read MoreHow Peripheral Eosinophil Counts Can Pinpoint COPD Subtype
High peripheral eosinophil counts could help identify patients with COPD and eosinophilic inflammation, irrespective of asthma history, according to new research.
Read More
Diagnosing, Managing Asthma During COVID-19
Objective tools that are useful in making a diagnosis and in management of asthma include spirometry and fractional exhaled nitric oxide (FeNO). However, there are complications and challenges in obtaining patient data with the changes brought by the COVID-19 pandemic.
Read More
Diagnosing and Managing Asthma
Objective tools that are useful in making a diagnosis and in management of asthma include spirometry and Fractional exhaled nitric oxide (FeNO). However, there are complications and challenges in obtaining patient data with the changes brought by the COVID-19 pandemic.
Read More
Caire Inc Acquires Spirosure FeNO Device
Caire Inc has acquired Spirosure Inc, a California-based developer and manufacturer of the Fenom Pro FeNO device used to detect allergic inflammation in asthmatic patients.
Read More
Vyaire to Market FeNO Device for Asthma Monitoring
Vyaire Medical Inc will now be the exclusive distributor of the Fenom Pro Asthma Monitor, a fractional exhaled nitric oxide (FeNO) device manufactured by Spirosure Inc.
Read More
FeNO May Help Diagnose Cough Variant Asthma
FeNO may be useful for diagnosing cough variant asthma in patients with chronic cough who have normal spirometry.
Read More
GINA Recommends FeNO Monitoring for Severe Asthma
Fractional exhaled nitric oxide (FeNO) monitoring has been recommended for the management of difficult-to-treat and severe asthma in adolescent and adult patients by the Global Initiative for Asthma (GINA).
Read More
FeNO Testing Now Available to Aetna-insured Patients
Aetna has updated its Exhaled Breath Tests Clinical Policy to include the measurement of exhaled nitric oxide (FeNO) as “medically necessary” for the evaluation of asthma.
Read More
FeNO Useful in Cough Treatment
Levels of fractionated exhaled of nitric oxide (FeNO) can indicate whether patients with unexplained coughs need treatment with inhaled corticosteroids.
Read More
Niox Vero FeNO Device Now Available through Vizient Inc
Circassia Pharmaceuticals Inc has received a multiyear Innovative Technology contract for its Niox Vero asthma management products from Vizient Inc.
Read More
Aerocrine Receives Clearance for FeNO Device in Japan
The use of Aerocrine’s FeNO-measuring device NIOX VERO as a tool for assessing patients with allergic airway inflammation has been cleared by Japanese health authorities.
Read More
Major US Insurance Provider to Cover FeNO Test For Asthma
Health Care Service Corporation will begin covering FeNO testing for asthma diagnosis and management effective April 1, 2014, according to a press announcement by Aerocrine.
Read More
Combining Results from 2 Asthma Tests Improves Diagnosis
Researchers found that fractional exhaled nitric oxide (FeNO) and B-Eos values signal 2 different inflammatory processes but when used in combination, the chances of the patient receiving the correct diagnosis and treatment for asthma increase.
Read More
FeNO Testing: A New Biomarker for Inflammation Enhances Asthma Diagnosis and Management
Point-of-care FeNO testing is easy and fast, and adds a reliable and objective measure to the clinical evaluation of airway inflammation.
Read MoreMeasuring Increased Levels of Exhaled Nitric-Oxide
A challenge test performed on sensitized patients determines whether various allergens and irritants cause an increase in exhaled nitric-oxide.
Read More